Compare TRVG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | PRLD |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 218.0M |
| IPO Year | 2015 | 2020 |
| Metric | TRVG | PRLD |
|---|---|---|
| Price | $2.82 | $4.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.95 | ★ $5.67 |
| AVG Volume (30 Days) | 23.4K | ★ 513.4K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $15.59 | $320.10 |
| Revenue Next Year | $8.42 | $100.00 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $2.59 | $0.75 |
| 52 Week High | $5.27 | $5.54 |
| Indicator | TRVG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 58.58 |
| Support Level | $2.77 | $1.09 |
| Resistance Level | $2.92 | $5.54 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.05 | 59.26 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.